Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada

The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited and remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) is Canada’s first and only approved oral hypomethylating agent for MDS and CMML. We characterized the real-world use of DEC-C thr...

Full description

Bibliographic Details
Main Authors: John Paul Yun, Philip Q. Ding, Aastha Dolley, Winson Y. Cheung
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Current Oncology
Subjects:
myelodysplastic syndrome
chronic myelomonocytic leukemia
real-world evidence
hypomethylating agents
treatment patterns
patient support programs
Online Access:https://www.mdpi.com/1718-7729/30/9/581

Internet

https://www.mdpi.com/1718-7729/30/9/581

Similar Items